- Apnimed aspires for up to $160M IPO as sleep apnea pill launch nearsApnimed has detailed its plans for an initial public offering, with the biotech intending to raise as much as $160 million to fund the launch of its sleep apnea pill.Fierce Biotech · 9h ago↗ source
- Argenx to pick up autoimmune biotech Forte Biosciences for $2.2BArgenx will spend $2.2 billion to buy Forte Biosciences and its anti-CD122 monoclonal antibody that’s under investigation for autoimmune diseases. The Belgian-Dutch pharma said Monday it will pay…Endpoints · 9h ago↗ source
- MapLight shares sink on mixed phase 2 schizophrenia readoutMapLight Therapeutics’ stock plummeted more than 60% this morning after the neuro outfit dropped mixed results for a phase 2 trial of its experimental schizophrenia treatment.